Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Immunohistochemical and Clinical Characterization of the Basal-like Subtype

ABSTRACT: 3 fresh frozen Breast tumor from the University of North Carolina at Chapel Hill (UNC) were obtained from the UNC Tissue Procurement Facility under an IRB approved protocol. Each experimental sample was ssayed versus a common reference sample that was a modified version of the Stratagene Human Universal Reference (which was further augmented with a 1/10 amount of MCF7 mRNA and 1/10 amount of ME16C mRNA) Keywords = Agilent microarray Keywords = EGFR Keywords = keratin Keywords: parallel sample

ORGANISM(S): Homo sapiens

SUBMITTER: Charles Perou

PROVIDER: E-GEOD-1319 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Nielsen Torsten O TO Hsu Forrest D FD Jensen Kristin K Cheang Maggie M Karaca Gamze G Hu Zhiyuan Z Hernandez-Boussard Tina T Livasy Chad C Cowan Dave D Dressler Lynn L Akslen Lars A LA Ragaz Joseph J Gown Allen M AM Gilks C Blake CB van de Rijn Matt M Perou Charles M CM

Clinical cancer research : an official journal of the American Association for Cancer Research 20040801 16

<h4>Purpose</h4>Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two associated with poor outcomes. Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors.<h4>Experimental design</h4>To identify an immunohistochemical profile for breast basal-like tumors, we c ...[more]

PMID: 15328174

Similar Datasets

Project description:Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. PIK3CA mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor-positive cancers (34.5%; P = 0.32), 17 of 75 HER-2-positive samples (22.7%; P = 0.04), 20 of 240 basal-like cancers (8.3%; P < 0.0001), and 0 of 14 claudin-low tumors (P = 0.004). Of 7 phosphatidylinositol 3-kinase/AKT pathway phosphorylation sites, 6 were more highly phosphorylated in MBCs than in other breast tumor subtypes. The majority of MBCs displayed mRNA profiles different from those of the most common, including basal-like cancers. By transcriptional profiling, MBCs and the recently identified claudin-low breast cancer subset constitute related receptor-negative subgroups characterized by low expression of GATA3-regulated genes and of genes responsible for cell-cell adhesion with enrichment for markers linked to stem cell function and epithelial-to-mesenchymal transition (EMT). In contrast to other breast cancers, claudin-low tumors and most MBCs showed a significant similarity to a "tumorigenic" signature defined using CD44(+)/CD24(-) breast tumor-initiating stem cell-like cells. MBCs and claudin-low tumors are thus enriched in EMT and stem cell-like features, and may arise from an earlier, more chemoresistant breast epithelial precursor than basal-like or luminal cancers. PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets. Comparison of reference samples against treatment

Dataset Information

Immunohistochemical and Clinical Characterization of the Basal-like Subtype

Publications

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure